Intraperitoneal gemcitabine pharmacokinetics: A pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 4, 2008, Pages 647-653

  Gamblin, T Clark ^a,e   Egorin, Merrill J ^a,b   Zuhowski, Eleanor G ^b   Lagattuta, Theodore F ^b   Herscher, Laurie L ^c   Russo, Angelo ^c   Libutti, Steven K ^c   Alexander, H Richard ^c   Dedrick, Robert L ^d   Bartlett, David L ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Gemcitabine; Intraperitoneal chemotherapy; Pancreatic cancer; Pharmacokinetics

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; DRUG METABOLITE; GEMCITABINE; GLUCOSE; LY 183997; LY 198791;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; ASCITES; CANCER PATIENT; CLINICAL ARTICLE; DIALYSATE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCIDENCE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS ADENOCARCINOMA; PERITONEAL FLUID; PILOT STUDY; PRIORITY JOURNAL; STEADY STATE; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ASCITIC FLUID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIALYSIS SOLUTIONS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PERITONEAL DIALYSIS; PILOT PROJECTS; SURVIVAL RATE;

EID: 47549100393     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0647-9     Document Type: Article

References (34)

1. HA Burris MJ Moore J Andersen 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 2403 2413
2. RL Dedrick 1986 Interspecies scaling of regional drug delivery J Pharm Sci 75 11 1047 1052
3. RL Dedrick 1985 Theoretical and experimental bases of intraperitoneal chemotherapy Semin Oncol 12 3 1 6
4. RL Dedrick CE Myers PM Bungay VT DeVita 1978 Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer Treat Rep 62 1 1 11
5. BJ Delauter RK Ramanathan MJ Egorin LL Stover EG Zuhowski W Plunkett WC Zamboni 2000 Pharmacokinetics of gemcitabine and 2′, 2′- difluorodexoyrindine in patient with ascites Pharmacotherapy 20 10 1204 1207
6. FV Fossella SM Lippman DM Shin 1997 Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small cell lung cancer J Clin Oncol 15 1 310 316
7. Gastointestinal Tumor Study Group 1988 Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group J Natl Cancer Inst 80 10 751 755
8. MR Green 1996 Gemcitabine safety overview Semin Oncol 23 5 32 35
9. R Grunewald H Kantarjian M Du K Faucher P Tarassoff W Plunkett 1992 Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study J Clin Oncol 10 406 413
10. V Heinemann LW Hertel GB Grindey W Plunkett 1988 Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′- difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine Cancer Res 48 14 4024 4031
11. V Heinemann Y Xu S Chubb A Sen LW Hertel GB Grindley W Plunkett 1990 Inhibition of ribonucleotide reductase in CCRF-CEM cells by 2′, 2′-difluorodeoxy-cytidine Mol Pharmacol 38 4 567 572
12. LW Hertel GB Boder JS Kroin SM Rinzel 1990 Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxyctidine) Cancer Res 50 14 4417 4422
13. A Jemal RC Tiwari A Ghafoor 2004 Cancer statistics, 2004 CA Cancer J Clin 54 8 29
14. DJ Klaassen JM MacIntyre GE Catton PF Engstrom CG Moertel 1985 Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintence 5-fluoruracil - an Eastern Cooperative Oncology Study Group J Clin Oncol 3 373 378
15. B Lund PE Kristjansen HH Hansen 1993 Clinical and preclinical activity of 2′, 2′-difuorodeoxycytidine (gemcitabine) Cancer Treat Rev 19 1 45 55
16. G Macchia V Valentini GC Mattiucci 2007 Preoperative chemoradiation and intra-operative radiotherapy for pancreatic carcinoma Tumori 93 1 53 60
17. CG Moertel S Frytak RG Hahn 1981 Therapy of locally resectable pancreatic carcinoma: a randomized comparison of high dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group Cancer 48 1705 1710
18. MJ Moore IF Tannock DS Ernst 1997 Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer J Clin Oncol 15 12 3441 3445
19. JD Murphy S Adusumilli KA Griffith 2007 Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer Int J Radiat Oncol Biol Phys 68 3 801 808
20. SR Pestieau OA Stuart D Chang 1998 Pharmacokinetics of intraperitoneal gemcitabine in a rat model Tumori 84 6 706 711
21. WF Regine RA Abrams 2006 Adjuvant therapy for pancreatic cancer: current status, future directions Semin Oncol 33 6 S10 S13
22. K Ridwelski F Meyer A Hribaschek 2002 Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurrence of peritoneal carcinomatosis J Surg Oncol 79 10 16
23. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistic review 1975-2002. Available at http://seer.cancer.gov/csr/1975_2002/
24. P Sabbatini C Aghajanian M Leitao 2004 Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial Clin Cancer Res 10 9 2962 2967
25. RM Schultz RL Merriman JE Toth JE Zimmermann 1993 Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts Oncol Res 5 6-7 223 228
26. YH Shaib JA Davila C Naumann H El-Serag 2007 The impact of curative intent surgery on the survival of pancreatic cancer patients: A US population-based study Am J Gastroenterol 102 1 6
27. TA Sohn CJ Yeo JL Cameron 2000 Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 567 579
28. WM Stadler T Kuzel B Roth 1997 Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer J Clin Oncol 15 11 3394 3398
29. AM Storniolo SR Allerheiligen HL Pearce 1997 Preclinical, pharmacologic, and phase I studies of gemcitabine Semin Oncol 24 S7-2 S77
30. A Sultana C Tudur Smith D Cunningham 2007 Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy Br J Cancer 96 8 1183 1190
31. L Toschi G Finocchiaro S Bartolini 2005 Role of gemcitabine in cancer therapy Future Oncol 1 1 7 17
32. AP Vennok MJ Egorin GL Rosner 2000 Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565 J Clin Oncol 18 14 2780 2787
33. VP Vyas EH Rubin R Zamek 2000 Intraperitoneal gemcitabine: phase I study Proc AACR 41 612 (Abstract)
34. TP Yeo RH Hruban SD Leach 2002 Pancreatic cancer Curr Probl Cancer 26 176